Govt tightens export ban norms for anti-malarial drug hydroxycloroquine
New Delhi: The government has tightened the export ban norms on anti-malarial drug hydroxychloroquine by including special economic zones (SEZs) under its prohibition ambit to ensure there is no shortfall during Covid-19 crisis.
US President Donald Trump has said that he has requested Prime Minister Narendra Modi to release the amount of Hydroxychloroquine ordered by the US after India last month banned the drugs for exports.
“I called Prime Minister Modi of India this morning. They make large amounts of Hydroxychloroquine. India is giving it a serious consideration,” Trump said at his daily news conference at the White House on Saturday.
With more than three lakh confirmed cases of coronavirus infection and over 8,000 fatalities, the US has emerged as the worst sufferers of the deadly coronavirus diseases to which there has been no cure.
The drug is also not allowed to be shipped by export oriented units (EOUs) or under any export promotion scheme.
“The export of hydroxycloroquine and formulations made from hydroxycloroquine…is no longer allowed from SEZs/EOUs or against Advance Authorisation or against full advance payment…The export shall remain prohibited without any exception,” the directorate general of foreign trade (DGFT) has said in a notification.
Under advance authorisation (AA) scheme, firms are allowed to import raw material at zero duty but with the condition of export obligation within a certified time frame. SEZs are treated as foreign territory in terms of customs laws.
Normally export ban or restrictions imposed by the government does not apply on these zones as well as EOUs, which are specially meant to promote outbound shipments from the country.
In the case of export restrictions imposed on certain APIs and formulations, the government clarified that these curbs would not be applicable for units in special economic zones (SEZs).
Exporters availing AA scheme benefits too get these exemptions. But now the government has decided to include all this under the ambit of export ban due to the outbeak of coronavirus and increase in demand for this medicine.
The move assumes significance as Indian Council of Medical Research (ICMR) had recommended the use of hydroxychloroquine for treating healthcare workers handling suspected or confirmed coronavirus cases and also the asymptomatic household contacts of the lab-confirmed cases.
On March 25, the government banned export of anti-malarial drug hydroxycloroquine with immediate effect to ensure sufficient availability of the medicine in the domestic market.
In that notification, the DGFT had stated that export will be permitted from the SEZ and EOUs and in cases where the outbound shipment is made to fulfill export obligation under any advance authorisation license issued on or before the date of this notification, which is March 25, 2020.
Exports were earlier also allowed by India to other countries on humanitarian grounds on case to case basis on the recommendation of the Ministry of External Affairs. Besides, it was allowed in case of shipments where irrevocable letter of credit has been issued or in case where full advance payment has been received by the exporter in India against specific shipment.
With Trump describing hydroxychloroquine as a “game changer” in the fight against COVID-19 and several countries, including India, approving it for emergencies, pharmacies are reporting a surge in demand for the drug yet to be proven as a cure for the virus.